Key Highlights
- Avidity Biosciences names John B. Moriarty, Jr. as Chief Legal Officer and Corporate Secretary.
- John B. Moriarty, Jr. brings almost 30 years of legal expertise to Avidity.
- Former General Counsel John W. Wallen III to transition as a consultant through year-end.
- Moriarty’s leadership will support Avidity’s clinical development programs and pipeline expansion.
Source: PR Newswire
Notable Quotes
- “His extensive legal expertise and experience in leading biopharmaceutical companies through transformational growth will be instrumental as we continue to advance our three clinical development programs for the treatment of three distinct rare muscle diseases, expand our pipeline utilizing our broad AOC platform and build an integrated global organization.” — Sarah Boyce, President and CEO at Avidity Biosciences
- “I am excited to join Avidity at such a pivotal time in the company’s transformation as it advances potential first-in-class and best-in-class therapies in development and prepares for global commercial execution.” — John B. Moriarty, Jr., Chief Legal Officer at Avidity Biosciences
SoHC's Take
The appointment of John B. Moriarty, Jr. as Chief Legal Officer and Corporate Secretary at Avidity Biosciences marks a significant step forward for the company. With nearly three decades of industry experience and a proven track record of guiding biotech firms through critical growth phases, Moriarty’s expertise is poised to support Avidity’s ambitious goals. His background in leading legal teams and enhancing corporate governance will be invaluable as Avidity advances its clinical development programs and expands its pipeline. This strategic addition to the leadership team underscores Avidity’s commitment to transforming the RNA therapeutics landscape with its innovative AOC platform.
